Podcast appearances and mentions of todd morgan

In this Bucket List Bit, Todd Morgan explores the hidden challenges of mental health support and reveals helpful ways to combat loneliness, especially in rural communities. From telehealth accessibility to the power of proactive connection, he shares insights about building meaningful relationships and spotting unique signs of struggle in different communities. Discover why sometimes being the first to reach out can create ripples of positive change.Listen to the full episode here:Listen on Apple PodcastsListen on SpotifyWatch the Episode On YouTubeLearn more about Todd Morgan

5 Solved True Crime Cases #1 - Carolyn Byington #2 - Gayle Barrus #3 - Saad Kawaf #4 - Todd Morgan #5 - Trevon Hall   Sources: https://controlc.com/01634448   Support the show Subscribe: ✅ https://www.youtube.com/c/SouthernGirlCrimeStories?sub_confirmation=1

Have you checked out the AUA/ASTRO/SUO's recently released guidelines for salvage therapy in prostate cancer biochemical recurrence? In this episode of the BackTable Urology Podcast, guest Dr. Todd Morgan from the University of Michigan and host Dr. Aditya Bagrodia continue with part two of our series on prostate cancer biochemical recurrence management. --- This podcast is supported by: Veracyte https://www.veracyte.com/decipher --- SYNPOSIS The doctors focus on the difficulty in declaring a patient 'cured' and the implications of biochemical recurrence after treatment. Dr. Morgan highlights the importance of PSA in the postoperative setting and explores the role of the Decipher Prostate Genomic Classifier in personalizing treatment. He talks through the latest AUA/ASTRO/SUO consensus on biochemical recurrence guidelines, including the significance of early salvage therapy and the integration of advanced imaging techniques like PSMA PET scans. Further, Dr. Morgan emphasizes the role for multidisciplinary evaluation, patient counseling, and future directions of research to refine treatment options. This discussion underscores the transition from adjuvant to early salvage radiation as a standard practice and considers emerging biomarker strategies to inform treatment decisions. --- TIMESTAMPS 00:00 - Introduction 03:41 - Consensus Biochemical Recurrence Guidelines 08:56 - Evolution of Post-Prostatectomy Biochemical Recurrence Management 13:24 - Patient Counseling and Risk of Recurrence 17:42 - PSMA PET Scans 20:44 - Postoperative PSA Monitoring 28:35 - The Role of Radiation 31:56 - Hormone Therapy 39:00 - Salvage Lymphadenectomy 46:30 - Future Directions and Concluding Thoughts --- RESOURCES Veracyte https://www.veracyte.com/ Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline (2024) https://www.auanet.org/guidelines-and-quality/guidelines/salvage-therapy-for-prostate-cancer

In this episode, Dr. Geo sits down with Dr. Todd Morgan, a leading urological surgeon from Michigan Medicine, to explore cutting-edge tools like biomarkers, MRI, and genomic testing in diagnosing prostate cancer. They dive into the benefits of active surveillance, the importance of the MUSIC trial, and how advanced diagnostics shape treatment decisions.Key Points:Importance of biomarkers and MRI in reducing unnecessary biopsies.Active surveillance for low-risk prostate cancer and the impact of the MUSIC trial.Use of genomic testing (Decipher, Prolaris) to inform treatment decisions.Debate around active surveillance for higher-risk Gleason 7 cancers.Role of AI and precision-based treatments in prostate cancer care.----------------We are excited to introduce our October Sponsors:XY Wellness: XY Wellness provides a high-value roadmap to health and wellness for men with prostate cancer. Co-founded by our Chief Medical Officer, they aim to help men thrive post-diagnosis. [Learn more about XY Wellness here [https://bit.ly/3uJPC7Z].AG1 (Athletic Greens): AG1 contains 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This special blend of ingredients supports your gut health, nervous system, immune system, energy, recovery, focus, and aging. All the things. Enjoy AG2 (Athletic Greens) [https://bit.ly/3mA2tVV] here----------------Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube Channel to get more content like this and learn how you can live better with age.You can also listen to this episode and future episodes of the Dr. Geo Podcast by clicking HERE.----------------Follow Dr. Geo on social media. Facebook, Instagram Click here to become a member of Dr. Geo's Health Community.Improve your urological health with Dr. Geo's formulated supplement lines:XY Wellness for Prostate cancer lifestyle and nutrition: Mr. Happy Nutraceutical Supplements for prostate health and male optimal living.You can also check out Dr. Geo's online dispensary for other supplement recommendations Dr. Geo's Supplement Store____________________________________DISCLAIMER: This audio is educational and does not constitute medical advice. This audio's content is my opinion and not that of my employer(s) or any affiliated company.Use of this information is at your own risk. Geovanni Espinosa, N.D., will not assume any liability for any direct or indirect losses or damages that may result from the use of the information contained in this video, including but not limited to economic loss, injury, illness, or death.

Let's dive into the nuances of government affairs for landmen with Todd Morgan! Discover the legislative battles, evolving landman roles, and critical lobbying efforts keeping the industry thriving. Don't miss it! Time Stamps01:32 - Episode & Guest Intro02:23 - Todd Morgan's Background and Career05:52 - The Role of a Lobbyist12:35 - Legislative Processes and Relationships22:59 - Licensing and Regulation Issues 28:11 - Current Legislative Climate30:39 - Importance of Lobbying for Landmen35:07 - Political Landscape and Challenges 40:38 - Inside Legislative Negotiations48:12 - Lobbying for the Renewables51:53 - Landmen and Industry Evolution56:16 - Digitization and Modern Challenges57:10 - Rare Earth Minerals and Legalities01:01:30 - Episode OutroHelp us improve our podcast! Share your thoughts in our quick survey.ResourcesNeed Help With A Project? Meet With DudleyWatch On YoutubeFollow Dudley Land Co. On LinkedInSubscribe To Our Newsletter, The Land Dept. MonthlyHave Questions? Email usMore from Our GuestTodd Morgan on LinkedInMore from Our HostsConnect with Brent on LinkedInConnect with Khalil on LinkedIn

Did you know?Suicide is the leading cause of death for young Australians, with most mental health battles starting before 25. While sobering, there is light ahead.Joining us with hope and purpose is Todd Morgan, CEO of Outside the Locker Room. They aim to rewrite the story around mental health by equipping individuals and communities to prioritise emotional wellbeing over stigma.This conversation explores the power of human connections, proactive support systems, and positive cultures to transform challenges into strengths. Todd shares his motivations for this mission and Outside the Locker Room's uplifting approach.Together, we can rewrite the mental health narrative. So tune into this solutions-focused chat as we gain insight, get equipped to take action, and spread more light.Episode Highlights:"If you can create a really good culture at work or sporting club or in some sort of community group or inside your own friendship group, that's the most important part." — Todd Morgan"The more vulnerable, the more authentic you are, the more it's you, the more it's heartfelt. That gives licence permission for the recipient, the kids in this case, to open up." — Trav Bell"It's the little moments. It's the little shares. It's the full on case studies that you hear the results of people later on down the track swinging back in and certainly back to you and sharing." — Trav Bell“Once you drop your ego, there's a direct correlation between how people will open up to you and how you'll start helping other people.” — Trav Bell“If you can't find it, be the first. Keep being the first, keep being the change you want to see in the world. You've got to take that first step.” — Todd MorganConnect with Todd Morgan:LinkedIn: https://www.linkedin.com/in/todd-morgan-7b4a05191/Website: https://otlr.org.au/Facebook: https://www.facebook.com/OutsideTheLockerRoomYouTube: https://www.youtube.com/channel/UCXnktQFtm6gznYNY7Rt62HwInstagram: https://www.instagram.com/otlr/Connect with Trav Bell:Website - https://www.thebucketlistguy.com/LinkedIn - https://www.linkedin.com/in/travbell/Facebook - https://www.facebook.com/thebucketlistguyTwitter - https://twitter.com/TravBellInstagram - https://www.instagram.com/bucketlistguy.travbell/YouTube - https://www.youtube.com/user/TheBucketListGuy2011Podcast - https://podcasts.apple.com/us/podcast/the-bucket-list-life-helping-you-build-a-life-by-design/id1712886116Book - www.thebucketlistguy.com/book

Renu caught up with lots of experts and friends at ASCO GU in San Francisco recently and brings you all the highlights. Hear from Toni Choueiri, Matt Cooperberg (on that debate on renaming low-grade prostate cancer), Todd Morgan, Neha Vapiwala, Morgan Roupret, Sophia Kamran, Morgan Roupret, Sam Washington, plus a great chat with Tyler Seibert while they were out for an early morning run around beautiful San Francisco. Even better on our YouTube channelGU Cast Conference Highlights are supported by our Gold Partner, Bayer China. 

Todd Morgan has lost over 10 people in his life to suicides, overdosing or vehicle accidents. It just so happened that after one of those instances, a friend's mum encouraged Todd to step into the Mental Health Education space - after 12 years as a Strength & Conditioning Coach and Fitness Lecturer/Teacher. Fast forward to today, Todd is the CEO of Outside the Locker Room (OTLR), a charity that aims to provide greater mental health education to sporting clubs across Australia. In this episode, expect to learn about the intricacies to running a charity in Australia, why you are NOT unique and why the definition of 'mental health' has lost its way. Todd's Socials: Instagram (Personal) - https://www.instagram.com/t.morgan1/ Instagram (OTLR) - https://www.instagram.com/otlr/ Website - https://otlr.org.au/ Mates in March is a charity event for the month of March. Everything is better when done together, and in March, Outside the Locker Room is set on bringing mates together to over come challenges. Throughout the month of March, work alongside your mates to take on our challenge of 9 Days of 9 K's. If you are looking to start a conversation and save a life, grab a mate and run or walk 9km's per day, for any 9 days during the month of March. Set yourself a target, fundraise, share your progress, encourage others to join and connect your community. Interested? Sign up here - https://matesinmarch.com/ Remember if you enjoyed the episode, please don't forget to follow Life With Lam and leave a review. Contact me via these handles if you want to collaborate or be a part of the family! Instagram - https://www.instagram.com/lifewithlampodcast/ Email - lifewithlampodcast@gmail.com

Drs. Neeraj Agarwal and Todd Morgan discuss CONTACT-02, KEYNOTE-564, CheckMate-67T, and other notable studies featured at the 2024 ASCO Genitourinary Cancers Symposium, as well as additional key abstracts in prostate, kidney, and bladder cancers that will significantly influence clinical practice. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program and professor of medicine at the Huntsman Cancer Institute at the University of Utah, and editor-in-chief of ASCO Daily News. Today, we'll be discussing practice-changing abstracts and other key advances in GU oncology featured at the 2024 ASCO Genitourinary Cancers Symposium. Joining me for this discussion is Dr. Todd Morgan, the chair of this year's ASCO GU. Dr. Morgan is a urologic surgeon, chief of urologic oncology at Michigan Medicine, and a professor of urology at the University of Michigan. Our full disclosures are available in the transcript of this episode, and the disclosures of all guests on the podcast can be found at asco.org/DNpod. Todd, thank you for joining us today. Dr. Todd Morgan: Thanks so much, Neeraj. It's an honor to be here and I'm just thrilled to be able to do this with you. Dr. Neeraj Agarwal: Thank you. So, the GU meeting showcased significant advancements across the spectrum of GU malignancies. Can you tell us about the hot topics that captured the headlines this year? What did you find exciting this year at the ASCO GU Symposium? Dr. Todd Morgan: The theme of this year's meeting was "20 Years of Advancing Science and Transforming Patient Care," and this reflected ASCO GU's incredible milestone in GU cancer research over the last 2 decades. We were thrilled to welcome over 5,200 attendees from over 70 countries, and, believe it or not, there were more than 875 abstract submissions, compared to more than 300 in the meeting's first year. Most of the participants were present in person and that was fantastic. It enabled great networking opportunities and opportunities for experts, trainees, and mentees to exchange knowledge and ideas. Without a doubt, ASCO GU remains the annual meeting in our field, and it's amazing to hear the breadth and depth of the state-of-the-art science that's presented at this meeting, and so much of it impacts patient care the second that you return home. Additionally, the meeting's focus on diversity and interactivity, networking, multidisciplinary collaboration, and evidence-based care were absolutely phenomenal from my standpoint. We had a lunch session for women's networking that was a huge success—the first time we've done that. The keynote lecture by Dr. Cheryl Lee that talked about ensuring adequate representation in clinical trials was a huge hit, and we had tremendous positive feedback from that lecture. There were also multiple featured sessions on different diagnostic and therapeutic challenges in localized, recurrent, and advanced GU cancers. And, Neeraj, my personal favorite during the symposium is always the Trainee and Early-Career Networking Luncheon on the first day and then the additional networking luncheons on the 2 following days. I had great conversations with a ton of trainees and junior faculty, and I feel so fortunate for the opportunity to get to know the future superstars in our field. So I'd like to kick it back to you for a second because the first day started with a focus on prostate cancer and some of the key clinical trials. A great example is Abstract 17, which was the second oral presentation delivered, and really congratulations to you, Neeraj, on sharing the exciting data from the CONTACT-02 trial which we were eagerly awaiting. And I'd love to get your thoughts on the data that you presented. Could you tell us more about that trial? Dr. Neeraj Agarwal: Yes, Todd, I agree with you. It was such an exciting conference overall, and thank you for your leadership of this conference. So let's talk about the CONTACT-02 trial. It was a phase 3 randomized trial assessing the combination of cabozantinib and atezolizumab versus a second NHT in patients with metastatic castration-resistant prostate cancer after progression on one NHT. This patient population had to have extrapelvic soft tissue metastases, which could be liver metastases, lung metastases, or lymph nodal metastases, and about up to a quarter of patients had liver metastases. And overall, this was a high-risk patient population which was randomized to, as I said, cabozantinib plus atezolizumab versus a second line NHT. And these patients had received a prior NHT, mostly in the mCRPC setting.  The co- or dual primary endpoints were overall survival and progression-free survival (PFS). And a unique thing was that PFS was assessed only by RECIST 1.1 because, as per our discussions with regulatory authorities, the trial was focused on soft tissue metastases because of questions in the past that cabozantinib can affect bone lesions in an artifactual fashion, possibly concerns. That's why the PCWG 3 criteria were not used as the primary endpoint, but, of course, indeed used as another key endpoint, so we have information on both. Anyway, coming back to the endpoint 1:1 randomization. The randomization was stratified by presence or absence of liver metastases, prior docetaxel chemotherapy, and the setting in which NHT was given (mCSPC or CRPC). The PFS or primary endpoint was significantly improved with a 35% reduction in risk of progression or death with the cabozantinib-atezolizumab combination versus second NHT. And there was a trend for overall survival, with a hazard ratio of 0.79 favoring the cabozantinib-atezolizumab combination. Interestingly, all subgroups benefitted, regardless of age, region, site of metastases, but we decided to choose three clinical subgroups of interest such as patients with liver metastases, patients with prior docetaxel chemotherapy in the castration-sensitive setting, and bone metastases, and all these subgroups seemed to be benefitting with the strongest signal in the liver metastasis subgroup, with a 57% reduction in risk of progression or death, which I would argue we have never seen with any combination or any regimen in the metastatic prostate cancer setting yet, barring some targeted therapies in very selected patients. But overall, across the non-biomarker-selected patients, we have never seen this kind of signal. Toxicity — no discussion is complete without discussing toxicity, so I would like to highlight that. Safety signal — there were no new safety signals. The most common grade 3-4 adverse events were hypertension in 7%, anemia in 6%, which were similar in both arms, and, of course, diarrhea and fatigue in 4% each. And if we look at the secondary endpoints, such as time to chemotherapy and time to symptomatic skeletal events, they tended to favor the cabozantinib-atezolizumab. To sum it up, cabozantinib-atezolizumab showed a significant PFS benefit, with a 35% reduction in risk of progression or death, with a trend for overall survival in this patient population with an unmet need. So thank you so much, Todd, for allowing me to summarize the results of this trial. Dr. Todd Morgan: Yeah, wow. That's so impressive, and not surprising that you could so fluidly go right through all that data. Amazing. We heard some discussion of the NHT control arm in this trial. Could you discuss that for a bit? Because it obviously has implications on the similar control arm of other ongoing trials in this setting. Dr. Neeraj Agarwal: Absolutely. Pretty much all trials, every trial which has recently been reported or started in metastatic castrate-resistant prostate cancer have a similar second NHT arm. Whether there were multiple immunotherapy trials which we have just reported, or new trials which are starting or just started enrolling patients. And the reason for that is no randomized trial has ever shown superiority of docetaxel chemotherapy over a second NHT after failure of prior NHT in the mCRPC setting. That's number one. If you look at NHT as a control, it is accepted by health authorities globally with multiple recent trials which are just starting also having NHDR and it would not have been possible without the approval of global regulatory authorities across the world.  Then, if you look at the recently reported trial in the mCRPC setting with prior treatment with an NHT, there is an indication that chemotherapy may not be superior to NHT. For example, in the KEYNOTE-641 trial in patients with mCRPC with prior NHT, randomizing patients to enzalutamide plus pembrolizumab versus enzalutamide, the median PFS with enzalutamide was 9 months. This is very similar with docetaxel in patients randomized to docetaxel plus pembrolizumab versus docetaxel; the median PFS with docetaxel is 8 months or 8.3 months. And lastly, if you really want to have a comparison of chemotherapy with NHT which has been done after progression on NHT and docetaxel chemotherapy, so later line of mCRPC setting, that is the CARD trial, as you can imagine, cabazitaxel versus NHT, especially in patients with visceral metastasis, which was the point of discussion. For example, people may not feel comfortable randomizing patients to NHT compared to taxane. The hazard ratio for PFS supporting cabazitaxel was 0.79, so almost a 0.80 PFS hazard ratio, which we have never seen turning out to be a clinically significant benefit. So, if you combine all these data together, I think it was absolutely acceptable to us as investigators to have a second NHT as the control arm. And of course, when we are consenting the patient, we have to keep alternatives in mind, and we do talk about those alternatives with the patients. And if alternatives seem more applicable, we should not be talking to patients about those clinical trials or a given clinical trial in the clinic. I'm glad you brought this up, Todd, because this control NHT arm is not an issue with this trial, but all trials which should be presented in GU ASCO in the future meetings in the coming years. So, thank you. Dr. Todd Morgan: Yeah, thank you. It's such an important topic and controversy at some level, but it's a difficult problem to think about and obviously highly relevant to all the trials that we're looking at. Congrats again on that trial, that's tremendous. There was another important randomized phase 3 trial and it covers radiotherapy in patients with high-risk localized prostate cancer. Can you give us your insights on that one? Dr. Neeraj Agarwal: Yeah, Todd, I think you are referring to LBA259, titled "Long-term Results of Dose Escalation of Radiation Therapy from 70 Gy to 80 Gy Combined with Long-term Androgen Deprivation Therapy in High-risk Prostate Cancer: The GETUG-AFU 18 Randomized Trial." As you mentioned, in this randomized phase 3 trial, Dr. Christophe Hennequin and colleagues randomized patients with high-risk prostate cancer, which means they had to have either clinical stage T3 or T4 disease, or PSA ≥20 nanograms per milliliter, or a Gleason score between 8 and 10. These patients were randomized to receive ADT for 3 years combined with either dose-escalated intensity-modulated radiotherapy. So, I'd like to highlight, this was in the context of IMRT in the dose of 80 Gy or a conventional dose of 70 Gy. Now, you can argue that more people are using more than 70 Gy nowadays, but across the world, the conventional dose is still considered 70 Gy. So, 80 Gy versus 70 Gy were tested. Patients also had to have negative lymph node status on CT scans and MRI. The primary endpoint was biochemical progression-free survival or clinical progression-free survival at 5 years following the ASTRO Phoenix definition. Secondary endpoints – and these are quite important secondary endpoints – include overall survival, acute and late toxicity, and quality of life. The best part is that this trial met its primary endpoint with a 44% reduction in risk of biochemical or clinical progression or death in the dose-escalation radiotherapy arm compared with the conventional radiotherapy arm. Interestingly, a significant 52% improvement in prostate cancer-specific survival and a 39% improvement in overall survival was observed in the dose-escalated arm. So, 80 Gy continued to be superior to 70 Gy IMRT across the primary and secondary endpoints. Now, the best part is, regarding the toxicity profile, there was no significant difference between the 2 arms, with 78% of patients in the higher dose arm and 76% of patients in the conventional arm experiencing grade 2 or more toxicities. Dr. Todd Morgan: Great summary and really important, great news for our patients. Of course, it's a slightly different setting as it's high-risk localized prostate cancer. I checked in with our radiation oncologists at the University of Michigan after that [presentation] because I couldn't remember exactly where we are in terms of dose on these patients. And they were like, “Yeah, we've been doing 80 to 90 Gy for several years,” so it's great having this data to support that. And I think, as you said, the field at many centers has already moved that way. And again, the key takeaway from this abstract would be that IMRT, in combination with long-term androgen deprivation therapy, is effective and safe and increases not only the biochemical or clinical PFS rate, but also the cancer-specific survival and overall survival, again, in high-risk localized prostate cancer patients. And it does not appear to increase long-term toxicity. So really important. It'd be great to switch gears and discuss kidney cancer, if that's okay, and talk about some key abstracts in that field. What do you think? Dr. Neeraj Agarwal: There were so many exciting data in all cancers, which is amazing. So, Todd, could tell us about the LBA359, which I thought was one of the most impactful abstract presentations in the ASCO GU this year. It was titled, “Overall Survival Results from the Phase 3 KEYNOTE-564 Study of Adjuvant Pembrolizumab Versus Placebo for Treatment of Clear Cell Renal Cell Carcinoma (ccRCC)."   Dr. Todd Morgan: Yeah, this was a really big moment in our field, complete with a mid-presentation round of applause that was well deserved. And so this abstract was presented by Dr. Toni Choueiri from Dana-Farber Cancer Institute, and it included patients with clear cell renal cell carcinoma at intermediate high or high risk of recurrence, meaning that they had positive nodal disease or negative nodal disease with PT 2 and grade 4, or sarcomatoid features, or stage PT 3 or 4. These patients underwent nephrectomy with or without metastasectomy less than 12 weeks before randomization and had not received prior systemic therapy for clear cell RCC. Patients were randomized to receive either pembrolizumab 200 milligrams or placebo IV every three weeks for at least 17 cycles, or until disease recurrence, intolerable toxicity, or withdrawal of consent. Disease-free survival by investigator assessment was the primary endpoint, and overall survival was a key secondary endpoint. In this abstract, Dr. Choueiri and colleagues report results of the third prespecified interim analysis with a median follow-up of around 57 months in 496 patients receiving pembrolizumab and 498 patients receiving placebo. So, just as a reminder to the audience here, the first interim analysis reported at a median follow-up of 24 months and showed a significant reduction of 32% in the risk to recurrence or death in patients in the pembrolizumab arm. Then subsequently in November of 2021, the FDA approved pembrolizumab for the adjuvant treatment of patients with RCC who are at intermediate high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. At that time, though, overall survival data were still immature. So, at the third prespecified interim analysis with a median follow-up of around 57 months, pembrolizumab showed, for the first time in an adjuvant RCC setting, improved overall survival with a 38% reduction in the risk of death. The estimated OS rate at 48 months was 91.2% with pembrolizumab and 86% with placebo. Furthermore, the OS benefit was observed across key subgroups, including patients with non-metastatic disease, patients with metastatic but no evidence of disease, patients with PDL-1 combined positive score less than or greater than or equal to one, and patients with presence or absence of sarcomatoid features. In each of these subgroups, the forest plot looks really impressive. And the DFS benefit was similar to previously reported interim analyses with a hazard ratio of 0.72. Also, no new safety signals with pembrolizumab were observed so just tremendous data. Dr. Neeraj Agarwal: Thank you, Todd, for such a great summary of these very important results. So the key message from this abstract, as you said, is that after a median follow-up of around 57 months, which is a long follow-up, adjuvant pembrolizumab demonstrates a statistically significant and clinically meaningful improvement in overall survival versus placebo in patients with RCC at high risk of disease recurrence after surgery. And this is, by the way, the first phase 3 study to show improved overall survival with any adjuvant therapy in RCC. Basically, this means we should continue to use adjuvant pembrolizumab or at least bring it up in our discussion with our patients who are in a similar situation with high-risk RCC after surgery. So this is great news overall. Todd, there was another kidney cancer abstract, LBA360, which compared, interestingly, subcutaneous nivolumab with intravenous nivolumab in patients with metastatic renal cell carcinoma. Could you please give us your insight about this abstract?   Dr. Todd Morgan: Sure. Really interesting study. Really interesting data that were presented. So as you mentioned, CheckMate 67T was a multicenter, randomized, open-label phase three study led by Dr. Saby George and colleagues that evaluated pharmacokinetics and objective response rate non-inferiority of subcutaneous nivolumab versus IV nivolumab in patients with locally advanced or metastatic clear cell RCC. So patients with measurable disease that progressed during or after 1 to 2 prior systemic regimens and who did not receive a prior immuno-oncology treatment were randomized 1-1 to receive either subcutaneous nivolumab 1200 milligrams every 4 weeks or IV nivolumab 3 milligrams per kilogram every two weeks until disease progression, unacceptable toxicity, withdrawal of consent, completion of two years of treatment, or death. The coprimary pharmacokinetics endpoints for non-inferiority testing were time-average serum concentration over the first 28 days and minimum serum concentration at steady state determined by a population pharmacokinetics analysis. A key secondary endpoint was objective response rate by independent review. So in 248 patients receiving subcutaneous nivolumab and 247 patients receiving IV nivolumab, non-inferiority for the coprimary pharmacokinetics and key-powered secondary objective response rate endpoints were met. The relative risk ratio for objective response rate was 1.33. The median PFS by independent review was 7.23 months in the subcutaneous group and 5.65 months in the IV group. Treatment-related serious adverse events occurred in 6.5% of patients in each group, and study drug toxicity led to 3 deaths in the subcutaneous group and 1 death in the IV group. These results could support using subcutaneous nivolumab as a new option to improve healthcare efficiency, especially since the average injection time with subcutaneous nivolumab was less than 5 minutes. I think we all know what issues are going on in infusion beds across the country, including, I'm sure, your center and mine. Dr. Neeraj Agarwal: Yes, absolutely. I think this is great news for our patients, Todd. Thank you. This shows that we are not only improving therapeutic options and diagnostic tools, but maybe we're also on the right track towards more practical administration routes, assisting in addressing the treatment burden and improving the efficiencies of healthcare systems. We love to have this option available for our patients, especially those who are pressed for time. So, Todd, would you like to move on to bladder cancer now?  Dr. Todd Morgan: Yeah, Neeraj, that'll be fantastic. I'm sure listeners would love to hear more about LBA530. Could you tell us more about this one, Neeraj? Dr. Neeraj Agarwal: Of course. I think this abstract is titled "Enfortumab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Previously Untreated, Locally Advanced or Metastatic Urothelial Carcinoma: Subgroup Analysis Results from EV-302," which was a global phase three study and was presented by Dr. Michiel Van Der Heijden. As our audience may recall, the EV-302 trial was presented at the ESMO 2023 meeting by Dr Tom Powles and the results were very exciting where, for the first time, a combination outperformed traditional gemcitabine-cisplatin chemotherapy. In this trial, patients with previously untreated with metastatic advanced urothelial carcinoma were randomized 1-1 to receive a 3-week cycle of a combination of enfortumab vedotin, which, as we know, is an antibody-drug conjugate targeting nectin-4 expressed on the cancer cells and pembrolizumab, which is a PD-1 inhibitor, versus gemcitabine and cisplatin or carboplatin, which were, until recently, the standard of care in this setting, and continue to be so in many countries in the world. The combination of enfortumab and pembrolizumab reduced the risk of progression or death by 55% and reduced the risk of death by 53% in the overall population. So consistent decrease in the hazard ratios for PFS and OS, and consistent improvement in overall survival and PFS in that previously reported presentation in the ESMO 2023. Now, based on these results, this combination was recently approved by the FDA in December 2023 for patients with advanced or metastatic urothelial carcinoma. So now the abstract, which was presented at the ASCO GU 2024 meeting, reported the results of a prespecified subgroup analysis. Select secondary endpoints included objective responses, duration of response, and safety. In 442 patients receiving the combination of enfortumab vedotin plus pembrolizumab, and a similar number of patients receiving chemotherapy both PFS and OS were higher for the combination of EV and pembro among prespecified subgroups such as race, platinum eligibility, PDL-1 expression, metastatic site, involvement of the liver or kidney function. Interestingly, the combination of EV and pembro reduced the risk of death by 53% in patients with visceral metastasis and 54% in patients with node-only metastasis. The improvement in PFS seems to be consistent regardless of the site of metastasis. In patients with moderate to severe renal function, the risk of death was reduced by 50% in patients receiving combination therapy. This is one of the best findings of these results because we always face challenges in treating patients with suboptimal kidney function and we cannot use cisplatin. Overall, EV plus pembro continues to show superior efficacy compared to platinum-based regimens across subgroups across the subgroups across the site of metastasis regardless of kidney function and so on. Dr. Todd Morgan: Yeah, just amazing data. I love hearing you spell it out like that. So, thank you again for the opportunity for me to sit here with you and listen to you talk about these data. It's impressive that we have been able to expand our therapeutic arsenal for urothelial carcinoma with an immune-targeting regimen that can spare our patients potential side effects of chemotherapy. What would your final takeaway on this abstract be? Dr. Neeraj Agarwal: I agree with you, Todd. I would add that the OS benefit was consistently observed across these select prespecified subgroups, including those historically associated with poor prognosis. The results of this new analysis support the finding of primary results, which indicate that EV plus pembro is a potentially new standard of care for patients with newly diagnosed, locally advanced, or metastatic urothelial carcinoma. Before we wrap up the bladder cancer session and the podcast, Todd, could you please give us insights about LBA531? Dr. Todd Morgan: Yeah, absolutely. I loved getting to hear this abstract presented. This one is titled “Ambassador,” known as the AMBASSADOR trial aligns A031501, a phase 3 randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma versus observation, that was presented by Dr. Andrea Apolo. It's an open-label, randomized, phase 3 trial that included patients with muscle-invasive urothelial carcinoma of the bladder, upper tract, or urethra. Eligible patients had pathologic tumor stage T2 or greater and/or positive pathologic nodal disease or positive margins at surgery following neoadjuvant chemotherapy, or patients with pathologic tumor stage T3 or greater and/or positive pathologic nodal disease or positive margins at surgery without prior neoadjuvant chemotherapy, and who were cisplatin ineligible or declined adjuvant cisplatin-based therapy. These patients were randomized one to one to either receive pembrolizumab 200 milligrams every 3 weeks for 1 year or observation. The dual primary endpoints were disease-free survival and overall survival. Secondary objectives included evaluation of DFS and OS in PDL-1 positive and negative patients and assessing safety. A total of 354 patients were enrolled to receive pembrolizumab and 348 to the observation arm, and 21% of the patients in the observation arm received a subsequent immune checkpoint inhibitor. At a median follow-up of 22.3 months for DFS, the median disease-free survival in the pembrolizumab arm was 29 months, while it was only 14 months in the observation arm with a hazard ratio of 0.69. At the interim analysis, OS data showed only a trend toward better outcomes in the pembrolizumab arm, which did not, however, reach statistical significance, with a median of 50.9 months in the pembrolizumab arm and 55.8 months in the observation arm with a hazard ratio of 0.98. These results could nevertheless have been impacted by the subsequent treatment of patients in the observation arm with an immune checkpoint inhibitor, especially after the FDA approval of nivolumab in 2021 for patients with muscle-invasive urothelial carcinoma, based on results of the CheckMate 274 trial. In terms of the safety profile, grade three or more adverse events occurred in 48.4% of patients in the pembrolizumab arm and 31.8% of patients in the observation arm. Dr. Neeraj Agarwal: That's great, Todd. This is such a great summary of this trial, and this is exciting news for our patients with muscle-invasive urothelial carcinoma. I'm hoping that pembrolizumab will be another option for our patients when we are discussing adjuvant immunotherapy in the clinic, moving forward very soon. With that, we have covered several abstracts addressing prostate, bladder, and kidney cancer, significantly influencing our medical practices, at least at the current moment or in the near future. Todd, thank you for sharing your insights today. These are undoubtedly exciting updates for all members of the GU oncology community, and we are grateful for your valuable contribution to the discussion. Many thanks. Dr. Todd Morgan: Thanks, for having me, Neeraj; this was really fun. I'm just really proud and excited to still be part of this field, to be part of the GU oncology field, and it continues to be exciting for all the folks who are coming up. Dr. Neeraj Agarwal: Indeed. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Thank you very much.   Disclaimer: The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:   Dr. Neeraj Agarwal @neerajaiims   Dr. Todd Morgan @wandering_gu   Follow ASCO on social media:   @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn       Disclosures:    Dr. Neeraj Agarwal:    Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences    Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas   Dr. Todd Morgan: Consulting or Advisory Role: Myriad Genetics, MDxHealth, TerumoBCT Research Funding (Institution): Prostate Cancer Foundation, National Institutes of Health, Department of Defence, GenomeDX Biosciences, Myriad Genetics, MDxHealth  

Todd Morgan, Editor of the Walsh County Record, shares his conversion story

"And Taught Them Saying..." - The Scripture Lesson: Matthew 5:1-16 Message from Todd Morgan.

This week on BackTable Urology, Dr. Kristen Scarpato (Vanderbilt University), Dr. Todd Morgan (University of Michigan), and Dr. Philip Kim (Kaiser Permanente) discuss their urologic oncology fellowship experiences, the importance of mentorship, and work-life balance as urologists. --- SHOW NOTES First the doctors discuss the changing landscape of urologic oncology fellowships and the favorable job market for those graduating from residency. They also share how their experiences in residency and mentorship from esteemed urology professionals shaped their paths towards urologic oncology. Additionally, they discuss the Society of Urologic Oncology (SUO) Clinical Trials Consortium and its role in providing education and resources to fellows. Benefits of joining an SUO fellowship program include the ability to participate in clinical trials and gain mentorship opportunities. Finally, the doctors examine the reality of balancing early career work and family responsibilities. They analyze the effect of burnout on our work-life balance and the different stages of career and family life. They conclude the episode by emphasizing the importance of intentionality in both aspects of their lives. --- RESOURCES SUO Clinical Trials Consortium https://suoctc.org/home.aspx

How can organisations best promote their employees' mental well-being? Remote working and the challenges of the digital era have thrown up a new set of challenges. In another thought-provoking episode of The Learning Curve, Kenny talks with Todd Morgan, CEO of Outside The Locker Room (OTLR). As a charitable organisation, OTLR helps sporting clubs, schools and businesses across Australia change the game for mental health. Todd highlights the impact of technology on social connections and the rise of severe loneliness and poor mental health among employees who work remotely. But is it all bad? There's an increased awareness of companies in investing in the mental well-being of their employees. Todd offers practical advice and highlights the potential for digitalisation offer a more accessible and scalable approach to mental health training. Implementing a Learning Management System (LMS), for example, can help companies deliver mental well-being education can also be a valuable tool for supporting individuals' mental health. Listen in to find out more.

In this dynamic episode, I have the privilege of engaging in a candid dialogue with Todd, a driving force behind the impactful organization "Outside the Locker Room." Together, we explore the multifaceted world of mental health, sports, and personal well-being. Todd shares profound insights into the essence of happiness – what it truly means and how it intertwines with our everyday lives. Drawing from his experiences and expertise, he reveals invaluable strategies to foster happiness, both on and off the field. "Outside the Locker Room" is on a mission to revolutionize the culture within sports. Tune in as Todd discusses the pivotal role of fostering a supportive and empathetic environment, where mental health takes center stage alongside athletic prowess. Discover how this remarkable charity is effecting positive change, one conversation at a time. In an era where mental health education is paramount, we delve into the significance of spreading awareness, destigmatizing conversations, and empowering individuals with the knowledge they need. Todd's insights shed light on how "Outside the Locker Room" is playing a pivotal role in equipping athletes, coaches, and enthusiasts with the tools to navigate their mental well-being journey. Please be aware that this episode includes sensitive content, including discussions about mental health and mentions of suicide. If you or someone you know is struggling with these issues, it's important to reach out for appropriate support. This episode promises not only inspiration but also actionable takeaways to integrate well-being practices into your life and contribute to a transformative shift in sports culture. Join us for an eye-opening conversation that underscores the importance of prioritizing happiness, championing mental health, and igniting a cultural revolution in the world of sports, all with the guidance of "Outside the Locker Room." You can follow them on Instagram @otlr To keep up with the podcast follow the Instagram page @perfectly_flawed_podcast --- Send in a voice message: https://podcasters.spotify.com/pod/show/perfectly-flawed-podcast/message

In this episode of BackTable Urology, Dr. Aditya Bagrodia interviews Dr. Todd Morgan, chief of urologic oncology at the University of Michigan, about benefits and indications for germline testing in prostate cancer patients. --- SHOW NOTES First, the doctors discuss the formal definition of germline testing, which is identifying inherited DNA mutations known to be pathological. This is different from molecular testing, which detects molecular markers specific to tumor cells. The term “genomic testing” is a broad and vague term that may confuse patients. Germline testing may be beneficial to patients and their families by notifying them to undergo cancer screening earlier. 12% of metastatic prostate cancer patients and 5 to 10% of localized prostate cancer patients have a germline mutation. Next, they discuss critical criteria for germline testing besides having a high grade and high stage cancer. Dr. Morgan recommends germline testing for all prostate cancer patients with metastatic cancer. He also believes that taking a thorough family history is fundamentally important in deciding whether or not to order testing. He emphasizes the importance of collecting information about other family members with other types of cancer, their age of diagnosis, their relationship to the patient, and their mortality from cancer. Patients may not know family history well, but he has a low threshold of testing if he suspects a pattern of heritability. Then, Dr. Morgan explains how germline testing may affect decision making. For patients with localized and low risk disease, he notes that prompt treatment may be beneficial in patients with a BRCA2 mutation, but there is still not enough evidence to eliminate active surveillance as an option. For high-risk disease, he always recommends treatment over active surveillance, regardless of germline mutation. For patients who have a BRCA2 mutation but no diagnosis of prostate cancer, he counsels them in his high risk prostate clinic. These patients receive close screening measures, such as lower PSA level thresholds, identification of urine biomarkers, and MRI scans. Additionally, the doctors discuss various testing companies. They do not recommend using 23 and Me as a comprehensive screening panel because it is exceedingly limited in the germline mutations it tests. Dr. Morgan also emphasizes that as the ordering physician, he is responsible for giving the patient the result of the test. If there is a positive result on germline mutation testing, he refers the patient to genetic counselors, who are equipped to deal with conversations regarding mutations that have non-urological implications as well. Finally, they end the discussion by chatting about different research trials about germline testing.

"Who Can Tell" - The Scripture Lesson: Jonah 3:9 - Message delivered by Todd Morgan.

The annual Prostate Cancer Foundation (PCF) Retreat is in its 29th year, and is the showpiece event of the PCF's incredible research program. Each year, PCF investigators from around the world gather in California to share their work and interact together. Fair to say it has developed a legendary status among the prostate cancer community across the globe. GU Cast's Dr Renu Eapen has recently received a PCF Young Investigator Award to support her PhD into immunological aspects of prostate cancer in patients receiving Lu-PSMA on the LuTectomy trial, so she was excited to travel to Carlsbad (CA) to attend this year's PCF Retreat. She joined up with fellow Young Investigator Dr Edmond Kwan to bring us a few highlights from this year's meeting. Lots of familiar faces in there! Watch out for Felix Feng, Misha Beltran, Howard Soule, Andrea Miyahira, Todd Morgan, Chuck Ryan, Tyler Seibert, Alicia Morgans, Neeraj Agarwal, Gina Carithers and many more. Even better on our Youtube channel Links:The PCF Urotoday 

On this episode we chat with Todd Morgan from OTLR all about men's mental health

Appropriate use of Biomarker and Genetic Testing in the Diagnosis and Management of Patients with Prostate Cancer Host: Jay D. Raman, MD, FACS Co-Hosts: Veda Giri, MD and Todd Morgan, MD CME Available: auau.auanet.org/node/37313 At the conclusion of this activity, participants will be able to 1. Assess how to maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically meaningful prostate cancer while avoiding unnecessary biopsies and detection of clinically unimportant cancers. 2. Discuss the available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use and the clinical scenarios in which they are most valuable to be used. 3. Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 4. Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy and immunotherapy. ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Astellas AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. Pfizer, Inc. Sanofi Genzyme

Originally presented during the Residents Forum program at AUA2022 in New Orleans, this panel discussion features moderator Dr. Ruchika Talwar and guests Todd Morgan, MD; Yaw Nyame, MD, MS, MBA; Anne M. Suskind, MD, MS, FACS; and Gregory Tasian, MD as they discuss grant writing tips for residents.

Another guest episode! Yay! Today I have Todd Morgan with me. He is the CEO of the mental health organisation Outside The Locker Room (OTLR). OTLR aim to educate the community on the importance of mental health and breakdown any stigmas surrounding mental health. Today we focus on toxic masculinity, how this can impact mental health and how to support people around you to talk about their emotions.    Trigger warning: we do discuss mental health and suicide throughout this episode. If you need help or support at any time, please reach out to LifeLine on 13 11 14 today.    To find more from Todd and OTLR: Website: https://otlr.org.au  Insta: https://www.instagram.com/otlr/  For more info: https://www.healthline.com/health/toxic-masculinity#causes   Stay up to date with me @thehealthclassesyoumissed 

In our third episode, Allen is joined by VP of UKC Todd Kellam and special guest and former Hunting Ops team member in the 1990's Todd Morgan as we go on a deep dive into the history of the UKC Beagle Program. The roots of that program go back more than 30 years, and we'll discuss how this hunting program rose up from a few clubs to national-level events with the men who were there.

Lighting Ahead – Staging the future vehicle design In this week's episode of Autology, IHS Markit experts discuss with Todd Morgan, Chief Technology and Innovation Officer at Lumax Industries, how vehicle lighting is influencing the automotive design in the coming years. With new lighting and design concepts, the overall vehicle style is changing inside the cabin and outside. New lighting technologies are entering the stage to deliver better experiences with the car. Besides new freedoms in design, lighting can be used for communication. How do you imagine vehicles in the future will interact with occupants and other road users? New lighting technologies are entering faster than ever in volume vehicles and emerging markets. Can we expect further accelerations? We see that OEMs are accelerating their efforts of bringing EVs to market. How does this trend impact the lighting industry and emerging markets such as South Asia, where we see an increasing production volume while Europe and North America are stagnating? Tune in to find out the answers and much more! Speakers: Todd Morgan, Chief Technology and Innovation Officer at Lumax Industries Sascha Klapper, Lighting Senior Analyst at IHS Markit We'd love to hear your thoughts on this episode at our autology@ihsmarkit.com email, and you can find out much more across the autotechinsight.ihsmarkit.com website.

The city of Chattanooga has a rich architectural history. This episode is an interview with two people trying got preserve that history, Todd Morgan, Executive Director of the historic preservation organization Cornerstones, and Melisa Mortimer, the Development Review Planner for the City of Chattanooga Historic Zoning Commission. Chattanooga Civics is now on Patreon! Go to Patreon.com/ChattCivics For more civic resources visit ChattanoogaCivics.com Music credits: Loopster by Kevin MacLeod Link: https://incompetech.filmmusic.io/song/4991-loopster License: http://creativecommons.org/licenses/by/4.0/ Funk Game Loop by Kevin MacLeod Link: https://incompetech.filmmusic.io/song/3787-funk-game-loop License: http://creativecommons.org/licenses/by/4.0/

The HeForShe movement focused on the role of men on accelerating gender equality. Is it time to close up shop on this movement, or is there still work to do? If the work isn't done, what does getting it done look like?We continue the Michigan Women's Surgical Collaborative mini-series with a discussion about the role of men in helping female surgeons achieve. Featured speakers include:Lesly Dossett, M.D., M.P.H.Wes Ely, M.D., M.P.H.Jack Iwashyna, M.D., Ph.D.Kate Kraft, M.D.Todd Morgan, M.D. Click here for a transcript for this episode.Michigan Medicine is the academic medical center for the University of Michigan. See acast.com/privacy for privacy and opt-out information.

Dr. Todd Morgan is with us to talk about genetic testing for prostate cancer. The goal of this podcast is to help patients be better prepared to talk with their health care team about genetic testing in the treatment of prostate cancer. Short on time? Use the below timestamps to jump to any section: 0:27 - Dr. Morgan introduction 1:00 - Prostate cancer review 1:58 - Genetic testing review 3:17 - Value of this testing 5:43 - Genetic testing timing and treatment choices 7:23 - Who can be helped with genetic testing 8:38 - Who administers testing? Next steps for patients 11:30 - Talking with your doctor 13:09 - Should genetic testing be used to help prevent prostate cancer? 14:54 - Final thoughts For more information, please visit UrologyHealth.org and don't forget to subscribe to our free digital magazine, UrologyHealth extra. This podcast was supported by a charitable contribution by AstraZeneca. **** September 2, 2021

In this episode of CTM, Todd Morgan, National Programs Manager, for Outside the Locker Room, joins me in conversation via Zoomchat. Todd goes into detail with regards to the origins of Outside the Locker Room and how it was first formed. For those tuning in, that don't know a thing about OTLR, the idea / mission behind this non-for-profit charity is to "Deliver welfare and education programs that build both collective and individual mental health and wellbeing within our communities." - Outside The Locker Room. Todd outlines the educational programs that OTLR have put in place, to which they mainly revolve around the idea of everyone getting given a fair go, within sport. Whether you you have a form of disability, or are from a certain ethic group, everyone should be given a fair-go, an equal opportunity to play sports and to feel apart of that community. In this episode, we also cover the certain 'stereotypes' that some sporting clubs may potentially be well known for. Excessive drinking culture, drug indulging, racist remarking toward opposition. Whilst also openly sharing possible resolutions toward these issues, and how OTLR are trying to change these club cultures. One more pointer that I wanna pay mention too, is OTLR'S passion to helping people that may have set themselves a goal, to becoming a professional sporting athlete. It may have always been a dream of there's. However, they don't end up performing at the standard required, which resultantly see's them being delisted. OTLR provides assistance for individuals going through such a depressing, such a heart-breaking situation. The overall message of this Episode, is to not be afraid to reach out to those, that may or may not be in need of a conversation. Through the power of one random conversation, you might just infact help someone break an unhealthy habit of there's, or make them feel like as if someone finally wants to hear how there day was.

June 21, 2020 Embrace God, & All that that Entails - Todd Morgan

Todd Morgan talks about our relationship with God.

The Prez and VP are joined by Todd Morgan from Outside the Locker Room.

Making a Scene Presents an Interview with Val Starr Her ultra talented band is comprised of Sacramento blues professionals, John Ellis on bass, Tim Brisson on lead guitar, Frankie Munz on harmonica, and Paul Farman on drums. I Always Turn The Blues On also features several top Sacramento based side musicians including Todd Morgan of Todd Morgan & The Emblems on keys, Daniel Castro and Steve Wall on lead guitar, Guyle Taber on drums and Tim Barron on harmonica.

Host: Aaron Rittmaster Special Guest: Todd Morgan Aaron Rittmaster hosts the show solo for a discussion with Todd Morgan about Todd’s Christmas Holiday trip to Disneyland. It was Todd’s first visit to Disneyland Resort, and planned with only a few weeks notice. Thank you to the DISDads Podcast PLUS Sponsors, who help make this show […]

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/node/24582 Instructional Course Director(s) Todd Morgan, MD University of Michigan Instructional Course Faculty(s) Leonard Gomella, MD,FACS Professor And Chair Thomas Jefferson University Heather Cheng, MD, PhD University of Washington There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g. PARP inhibition), Urologists are suddenly being confronted with questions surrounding screening guidelines in men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations (present in greater than 10% of men with metastatic disease). This course will cover the state of the art in genetic testing and discuss the practical impact on patient care. Urologists will leave this course with a clear understanding of how to translate these latest scientific advances into their routine clinical practice, improving the care of these men who are at a markedly elevated risk of progression and death from prostate cancer. Learning Objectives: Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. Interpret results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy, and immunotherapy.

The City of Sacramento recently announced it would rethink its ordinance on buskers and outdoor music performers. It also hired a new "Creative Economy" director to think how arts and music can get a bigger boost here. But there are still some sour notes. The Police Department is still called out to turn the music down. Gentrification means long-time music venues are getting complaints from new neighbors. Local musicians say they lack community support due to a lack of small venues, rehearsal spaces and frugal audiences who don't want to pay. So what should Sacramento be doing to boost its local music scene, and its musicians? Should we look at top music towns like Austin or Nashville and follow their lead? Or are we doing just fine creating our own plan? We're talking with musicians, and the people who book and promote them, about how we can achieve perfect pitch in the capital city. Also, for this podcast, it was fitting to start and end it with music from Sacramento-based performers, so: Podcast intro music: "Turn Up" by Element Brass Band Podcast ending music: "Love and Affection" by Todd Morgan and the Emblems PANELISTS * Scott Brill-Lehn, concert promoter and owner of SBL Entertainment * Byron Colborn, baritone saxaphonist and bandleader of several local ensembles, including Element Brass Band and the Byron Colborn Big Band * Gabriell Garcia, co-owner of the Blue Lamp * Johnathon Glus, director of Cultural and Creative Economy for the City of Sacramento * Danielle Vincent, founder of First Festival and Show Up Sacramento * Paul Willis, local rapper, spoken-word artist, educator and activist PODCAST PLAY-BY-PLAY * O to 5 min - Intro to California Groundbreakers * 5 min - Panelists introduce themselves, and share their favorite summer songs * 10 min - What are Sacramento's music tastes overall, and how have they changed over the years? * 14 min - The pros and cons of putting on an all-local-music festival in Sacramento * 19:10 min - The pros and cons of running a live music venue in Sacramento * 24 min - The pros and cons of "making a survival" as a professional musician in Sacramento * 29:10 min - Racism in Sacramento's music scene * 35:45 min - How the City of Sacramento plans to promote and support the music scene * 42 min - What factors bring Sacramentans out to see music shows * 47:15 - Why can't more local bands open shows for national acts? * 53:45 - How parking and permit issues affect Sacramento's music scene * 1 hr, 3:45 min - How to set up the young musicians we're training to be successful, working artists * 1 hr, 21:15 min - How philanthropy and civic investment can help boost Sacramento's music scene

With Your Hosts, The Women of Wonders Bethany Schrader and Gayle Nicholson Today's guest will help us get ready for the most inspiring Holiday of Love of the Year. Valentines’ Day is only two weeks away and whether you are looking for, already with a special someone or looking to increase your capacity to love yourself, we have got something very special for you! Tune in this Wednesday for a whole new way to create the Energy of Love! Carolyn Melby ~ www.relationshipswithoutdating.com Todd Morgan ~ www.cyclingchef.com www.CheriLRTaylor.com     www.bethanyschrader.com/     www.gaylenicholson.com/     www.simonegers.com/

North American Deer Talk welcomes our newest sponsor Whitetail Exchange! Today we have Todd Morgan on the show to talk all things Whitetail Exchange.   Whitetail Exchange is an online auction that deals with everything Deer Farmers need for their farm. Whitetail Exchange is open for business 24 hours a day 365 days a year. […]

In this episode of Chairside Live, Dr. D finishes up Part II of his interview with Dr. Todd Morgan, as they discuss how to identify patients who could benefit from snoring and sleep apnea treatment. Then, in the Case of the Week, discover how a BruxZir® Solid Zirconia Crown is fabricated from start to finish. Watch Episode 121 of Chairside Live now!

On this week’s episode, Dr. DiTolla talks with Dr. Todd Morgan, a leading authority on snoring and obstructive sleep apnea treatment, to discuss everything from their time practicing together to Dr. Morgan’s first sleep appliance he improvised for his father before he got started in dental sleep medicine. In this episode’s Case of the Week, Dr. DiTolla praises a doctor’s preparation and impression that led to a successful case for the laboratory, doctor and patient. Watch Episode 120 of Chairside Live now!

Tune in to hear how Dr. Morgan got involved in this area of dentistry, the best way to incorporate this type of treatment into your practice, and why it can be a lifesaver for dentists who physically can’t or don’t want to do restorative dentistry anymore.